Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer

• Status: Recruiting
• Trial end date: 2026-11-30
• Target enrollment: 0
• Participant gender: Female

Summary

To investigate the efficacy of albumin-bound paclitaxel combined with carboplatin versus epirubicin combined with docetaxel as neoadjuvant therapy for triple-negative breast cancer.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shengjing Hospital
• Treatments: Albumin-Bound Paclitaxel; Carboplatin; Docetaxel; Epirubicin; Paclitaxel

Criteria

Inclusion Criteria:

• patients developing breast cancer as confirmed by X-ray examination, cancer tissue negative for estrogen receptor, progesterone receptor and HER2, and tumor stage II-III;

• estimated survival > 3 months;

• presence of clinically measurable lesions;

• Karnofsky functional status score ≥ 70;

• normal routine blood test results, normal liver and kidney function, and near normal electrocardiographic manifestations;

• age at 18-70 years.

Exclusion Criteria:

• stage IV breast cancer patients with bone metastasis or other distant metastasis;

• severe renal insufficiency;

• older adult patients with severe organic diseases such as heart and lung diseases, who are not estimated to be able to tolerate chemotherapy;

• those who have received antineoplastic therapy;

• those who have received neoadjuvant chemotherapy but fail in 2 cycles of neoadjuvant chemotherapy and switch to other regimens or terminate chemotherapy;

• those with history of other malignant tumors;

• those with severe heart, liver, and kidney organ dysfunction or poor health who cannot tolerate chemotherapy, or those who cannot tolerate chemotherapy and switch to other therapeutic regimens;

• those with mental and nervous system diseases who cannot comply with treatment;

• those with dexamethasone intolerance or those who are highly allergic to any drug in neoadjuvant chemotherapy;

• pregnant or lactating women;

• those who are participating in other trials.